Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 250

1.

Discovery of Metabolic Biomarkers Predicting Radiation Therapy Late Effects in Prostate Cancer Patients.

Cheema AK, Grindrod S, Zhong X, Jain S, Menon SS, Mehta KY, Suy S, Collins S, Wang Y, Timofeeva O, Bandi G, Pahira J, Kowalczyk K, Lynch J, Dritschilo A.

Adv Exp Med Biol. 2019;1164:141-150. doi: 10.1007/978-3-030-22254-3_11.

PMID:
31576546
2.

African-American Prostate Normal and Cancer Cells for Health Disparities Research.

Nicolas N, Upadhyay G, Velena A, Kallakury B, Rhim JS, Dritschilo A, Jung M.

Adv Exp Med Biol. 2019;1164:101-108. doi: 10.1007/978-3-030-22254-3_8.

PMID:
31576543
3.

Predictors of acute urinary symptom flare following stereotactic body radiation therapy (SBRT) in the definitive treatment of localized prostate cancer.

Repka MC, Kole TP, Lee J, Wu B, Lei S, Yung T, Collins BT, Suy S, Dritschilo A, Lynch JH, Collins SP.

Acta Oncol. 2017 Aug;56(8):1136-1138. doi: 10.1080/0284186X.2017.1299221. Epub 2017 Mar 8. No abstract available.

PMID:
28270015
4.

Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year Toxicity.

Paydar I, Pepin A, Cyr RA, King J, Yung TM, Bullock EG, Lei S, Satinsky A, Harter KW, Suy S, Dritschilo A, Lynch JH, Kole TP, Collins SP.

Front Oncol. 2017 Feb 7;7:5. doi: 10.3389/fonc.2017.00005. eCollection 2017.

5.

Cross-institutional knowledge-based planning (KBP) implementation and its performance comparison to Auto-Planning Engine (APE).

Wu B, Kusters M, Kunze-Busch M, Dijkema T, McNutt T, Sanguineti G, Bzdusek K, Dritschilo A, Pang D.

Radiother Oncol. 2017 Apr;123(1):57-62. doi: 10.1016/j.radonc.2017.01.012. Epub 2017 Feb 13.

PMID:
28202228
6.

Conditional reprogramming and long-term expansion of normal and tumor cells from human biospecimens.

Liu X, Krawczyk E, Suprynowicz FA, Palechor-Ceron N, Yuan H, Dakic A, Simic V, Zheng YL, Sripadhan P, Chen C, Lu J, Hou TW, Choudhury S, Kallakury B, Tang DG, Darling T, Thangapazham R, Timofeeva O, Dritschilo A, Randell SH, Albanese C, Agarwal S, Schlegel R.

Nat Protoc. 2017 Feb;12(2):439-451. doi: 10.1038/nprot.2016.174. Epub 2017 Jan 26.

7.

Conditionally reprogrammed normal and primary tumor prostate epithelial cells: a novel patient-derived cell model for studies of human prostate cancer.

Timofeeva OA, Palechor-Ceron N, Li G, Yuan H, Krawczyk E, Zhong X, Liu G, Upadhyay G, Dakic A, Yu S, Fang S, Choudhury S, Zhang X, Ju A, Lee MS, Dan HC, Ji Y, Hou Y, Zheng YL, Albanese C, Rhim J, Schlegel R, Dritschilo A, Liu X.

Oncotarget. 2017 Apr 4;8(14):22741-22758. doi: 10.18632/oncotarget.13937.

8.

Yttrium-90 radioembolization for colorectal cancer liver metastases in KRAS wild-type and mutant patients: Clinical and ccfDNA studies.

Janowski E, Timofeeva O, Chasovskikh S, Goldberg M, Kim A, Banovac F, Pang D, Dritschilo A, Unger K.

Oncol Rep. 2017 Jan;37(1):57-65. doi: 10.3892/or.2016.5284. Epub 2016 Nov 29.

9.

From Röntgen Rays to Carbon Ion Therapy: The Evolution of Modern Radiation Oncology in Germany.

Lischalk JW, König L, Repka MC, Uhl M, Dritschilo A, Herfarth K, Debus J.

Int J Radiat Oncol Biol Phys. 2016 Nov 15;96(4):729-735. doi: 10.1016/j.ijrobp.2016.08.026. Epub 2016 Aug 30. No abstract available.

10.

Proctitis 1 Week after Stereotactic Body Radiation Therapy for Prostate Cancer: Implications for Clinical Trial Design.

Paydar I, Cyr RA, Yung TM, Lei S, Collins BT, Chen LN, Suy S, Dritschilo A, Lynch JH, Collins SP.

Front Oncol. 2016 Jul 20;6:167. doi: 10.3389/fonc.2016.00167. eCollection 2016.

11.

Short DNA Fragments Are a Hallmark of Heavy Charged-Particle Irradiation and May Underlie Their Greater Therapeutic Efficacy.

Pang D, Chasovskikh S, Rodgers JE, Dritschilo A.

Front Oncol. 2016 Jun 10;6:130. doi: 10.3389/fonc.2016.00130. eCollection 2016.

12.

Acute Urinary Morbidity Following Stereotactic Body Radiation Therapy for Prostate Cancer with Prophylactic Alpha-Adrenergic Antagonist and Urethral Dose Reduction.

Repka MC, Guleria S, Cyr RA, Yung TM, Koneru H, Chen LN, Lei S, Collins BT, Krishnan P, Suy S, Dritschilo A, Lynch J, Collins SP.

Front Oncol. 2016 May 18;6:122. doi: 10.3389/fonc.2016.00122. eCollection 2016.

13.

Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: The Georgetown University Experience.

Mercado C, Kress MA, Cyr RA, Chen LN, Yung TM, Bullock EG, Lei S, Collins BT, Satinsky AN, Harter KW, Suy S, Dritschilo A, Lynch JH, Collins SP.

Front Oncol. 2016 May 6;6:114. doi: 10.3389/fonc.2016.00114. eCollection 2016.

14.

Radiation Metabolomics: Current Status and Future Directions.

Menon SS, Uppal M, Randhawa S, Cheema MS, Aghdam N, Usala RL, Ghosh SP, Cheema AK, Dritschilo A.

Front Oncol. 2016 Feb 2;6:20. doi: 10.3389/fonc.2016.00020. eCollection 2016. Review.

15.

Urethrogram-Directed Stereotactic Body Radiation Therapy for Clinically Localized Prostate Cancer in Patients with Contraindications to Magnetic Resonance Imaging.

Paydar I, Kim BS, Cyr RA, Rashid H, Anjum A, Yung TM, Lei S, Collins BT, Suy S, Dritschilo A, Lynch JH, Collins SP.

Front Oncol. 2015 Sep 1;5:194. doi: 10.3389/fonc.2015.00194. eCollection 2015.

16.

Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer.

Janowski EM, Kole TP, Chen LN, Kim JS, Yung TM, Collins BT, Suy S, Lynch JH, Dritschilo A, Collins SP.

Front Oncol. 2015 Jul 3;5:151. doi: 10.3389/fonc.2015.00151. eCollection 2015.

17.

Radiation Sensitization of Leukemic Cells for Low Dose Total Body Irradiation.

Janowski E, Dritschilo A.

EBioMedicine. 2015 Mar 13;2(4):278-9. doi: 10.1016/j.ebiom.2015.03.011. eCollection 2015 Apr. No abstract available.

18.

DNA studies using atomic force microscopy: capabilities for measurement of short DNA fragments.

Pang D, Thierry AR, Dritschilo A.

Front Mol Biosci. 2015 Jan 29;2:1. doi: 10.3389/fmolb.2015.00001. eCollection 2015. Review.

19.

Late urinary toxicity modeling after stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer.

Kole TP, Tong M, Wu B, Lei S, Obayomi-Davies O, Chen LN, Suy S, Dritschilo A, Yorke E, Collins SP.

Acta Oncol. 2016;55(1):52-8. doi: 10.3109/0284186X.2015.1037011. Epub 2015 May 14.

20.

Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer.

Gurka MK, Chen LN, Bhagat A, Moures R, Kim JS, Yung T, Lei S, Collins BT, Krishnan P, Suy S, Dritschilo A, Lynch JH, Collins SP.

Radiat Oncol. 2015 Feb 19;10:44. doi: 10.1186/s13014-015-0351-6.

21.

Knockdown of EphB1 receptor decreases medulloblastoma cell growth and migration and increases cellular radiosensitization.

Bhatia S, Baig NA, Timofeeva O, Pasquale EB, Hirsch K, MacDonald TJ, Dritschilo A, Lee YC, Henkemeyer M, Rood B, Jung M, Wang XJ, Kool M, Rodriguez O, Albanese C, Karam SD.

Oncotarget. 2015 Apr 20;6(11):8929-46.

22.

Stereotactic Body Radiation Therapy for Prostate Cancer: What is the Appropriate Patient-Reported Outcome for Clinical Trial Design?

Woo JA, Chen LN, Wang H, Cyr RA, Bhattasali O, Kim JS, Moures R, Yung TM, Lei S, Collins BT, Suy S, Dritschilo A, Lynch JH, Collins SP.

Front Oncol. 2015 Mar 31;5:77. doi: 10.3389/fonc.2015.00077. eCollection 2015.

23.

Rapid Prototyping of Nanofluidic Slits in a Silicone Bilayer.

Kole TP, Liao KT, Schiffels D, Ilic BR, Strychalski EA, Kralj JG, Liddle JA, Dritschilo A, Stavis SM.

J Res Natl Inst Stand Technol. 2015 Nov 17;120:252-69. doi: 10.6028/jres.120.015. eCollection 2015.

24.

Proctitis following stereotactic body radiation therapy for prostate cancer.

Joh DY, Chen LN, Porter G, Bhagat A, Sood S, Kim JS, Moures R, Yung T, Lei S, Collins BT, Ju AW, Suy S, Carroll J, Lynch JH, Dritschilo A, Collins SP.

Radiat Oncol. 2014 Dec 12;9:277. doi: 10.1186/s13014-014-0277-4.

25.

Prostate specific antigen kinetics following robotic stereotactic body radiotherapy for localized prostate cancer.

Kole TP, Chen LN, Obayomi-Davies O, Kim JS, Lei S, Suy S, Dritschilo A, Collins SP.

Acta Oncol. 2015 Jun;54(6):832-8. doi: 10.3109/0284186X.2014.983656. Epub 2014 Dec 3.

PMID:
25467965
26.

Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3)).

Janowski E, Chen LN, Kim JS, Lei S, Suy S, Collins B, Lynch J, Dritschilo A, Collins S.

Radiat Oncol. 2014 Nov 15;9:241. doi: 10.1186/s13014-014-0241-3.

27.

Improved irritative voiding symptoms 3 years after stereotactic body radiation therapy for prostate cancer.

Rana Z, Cyr RA, Chen LN, Kim BS, Moures RA, Yung TM, Lei S, Collins BT, Suy S, Dritschilo A, Lynch JH, Collins SP.

Front Oncol. 2014 Oct 21;4:290. doi: 10.3389/fonc.2014.00290. eCollection 2014.

28.

The induction of the p53 tumor suppressor protein bridges the apoptotic and autophagic signaling pathways to regulate cell death in prostate cancer cells.

Ringer L, Sirajuddin P, Tricoli L, Waye S, Choudhry MU, Parasido E, Sivakumar A, Heckler M, Naeem A, Abdelgawad I, Liu X, Feldman AS, Lee RJ, Wu CL, Yenugonda V, Kallakury B, Dritschilo A, Lynch J, Schlegel R, Rodriguez O, Pestell RG, Avantaggiati ML, Albanese C.

Oncotarget. 2014 Nov 15;5(21):10678-91.

29.

A dosimetric comparison of ultra-hypofractionated passively scattered proton radiotherapy and stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer.

Kole TP, Nichols RC, Lei S, Wu B, Huh SN, Morris CG, Lee S, Tong M, Mendenhall NP, Dritschilo A, Collins SP.

Acta Oncol. 2015 Jun;54(6):825-31. doi: 10.3109/0284186X.2014.953260. Epub 2014 Sep 17.

PMID:
25227898
30.

Late urinary symptom flare after prostate stereotactic body radiation therapy.

Collins SP, Suy S, Chen LN, Collins BT, Lynch J, Dritschilo A.

J Clin Oncol. 2014 Oct 20;32(30):3451-2. doi: 10.1200/JCO.2014.56.6547. Epub 2014 Sep 2. No abstract available.

PMID:
25185102
31.

Improved robotic stereotactic body radiation therapy plan quality and planning efficacy for organ-confined prostate cancer utilizing overlap-volume histogram-driven planning methodology.

Wu B, Pang D, Lei S, Gatti J, Tong M, McNutt T, Kole T, Dritschilo A, Collins S.

Radiother Oncol. 2014 Aug;112(2):221-6. doi: 10.1016/j.radonc.2014.07.009. Epub 2014 Aug 6.

PMID:
25108808
32.

Obstructive voiding symptoms following stereotactic body radiation therapy for prostate cancer.

Arscott WT, Chen LN, Wilson N, Bhagat A, Kim JS, Moures RA, Yung TM, Lei S, Collins BT, Kowalczyk K, Suy S, Dritschilo A, Lynch JH, Collins SP.

Radiat Oncol. 2014 Jul 24;9:163. doi: 10.1186/1748-717X-9-163.

33.

Significant disparity in base and sugar damage in DNA resulting from neutron and electron irradiation.

Pang D, Nico JS, Karam L, Timofeeva O, Blakely WF, Dritschilo A, Dizdaroglu M, Jaruga P.

J Radiat Res. 2014 Nov;55(6):1081-8. doi: 10.1093/jrr/rru059. Epub 2014 Jul 17.

34.

Patient-reported urinary incontinence following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer.

Chen LN, Suy S, Wang H, Bhagat A, Woo JA, Moures RA, Kim JS, Yung TM, Lei S, Collins BT, Kowalczyk K, Dritschilo A, Lynch JH, Collins SP.

Radiat Oncol. 2014 Jun 26;9:148. doi: 10.1186/1748-717X-9-148.

35.

Clinical characteristics and management of late urinary symptom flare following stereotactic body radiation therapy for prostate cancer.

Woo JA, Chen LN, Bhagat A, Oermann EK, Kim JS, Moures R, Yung T, Lei S, Collins BT, Kumar D, Suy S, Dritschilo A, Lynch JH, Collins SP.

Front Oncol. 2014 May 26;4:122. doi: 10.3389/fonc.2014.00122. eCollection 2014.

36.

Correlation of HOXD3 promoter hypermethylation with clinical and pathologic features in screening prostate biopsies.

Chen LN, Rubin RS, Othepa E, Cer C, Yun E, Agarwal RP, Collins BT, McGeagh K, Pahira J, Bandi G, Kowalczyk K, Kumar D, Dritschilo A, Collins SP, Bostwick DG, Lynch JH, Suy S.

Prostate. 2014 May;74(7):714-21.

37.

Hepatitis delta antigen requires a flexible quasi-double-stranded RNA structure to bind and condense hepatitis delta virus RNA in a ribonucleoprotein complex.

Griffin BL, Chasovskikh S, Dritschilo A, Casey JL.

J Virol. 2014 Jul;88(13):7402-11. doi: 10.1128/JVI.00443-14. Epub 2014 Apr 16.

38.

Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer.

Mouliere F, El Messaoudi S, Pang D, Dritschilo A, Thierry AR.

Mol Oncol. 2014 Jul;8(5):927-41. doi: 10.1016/j.molonc.2014.02.005. Epub 2014 Mar 24.

39.

Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer.

Bhattasali O, Chen LN, Woo J, Park JW, Kim JS, Moures R, Yung T, Lei S, Collins BT, Kowalczyk K, Suy S, Dritschilo A, Lynch JH, Collins SP.

Radiat Oncol. 2014 Feb 11;9:52. doi: 10.1186/1748-717X-9-52.

40.

A new role for STAT3 as a regulator of chromatin topology.

Zhao Y, Zeng C, Tarasova NI, Chasovskikh S, Dritschilo A, Timofeeva OA.

Transcription. 2013 Sep-Dec;4(5):227-31. No abstract available.

PMID:
24406340
41.

Rationale for stereotactic body radiation therapy in treating patients with oligometastatic hormone-naïve prostate cancer.

Bhattasali O, Chen LN, Tong M, Lei S, Collins BT, Krishnan P, Kalhorn C, Lynch JH, Suy S, Dritschilo A, Dawson NA, Collins SP.

Front Oncol. 2013 Dec 3;3:293. doi: 10.3389/fonc.2013.00293. Review.

42.

Potency preservation following stereotactic body radiation therapy for prostate cancer.

Obayomi-Davies O, Chen LN, Bhagat A, Wright HC, Uhm S, Kim JS, Yung TM, Lei S, Batipps GP, Pahira J, McGeagh KG, Collins BT, Kowalczyk K, Bandi G, Kumar D, Suy S, Dritschilo A, Lynch JH, Collins SP.

Radiat Oncol. 2013 Nov 1;8:256. doi: 10.1186/1748-717X-8-256.

43.

DIM (3,3'-diindolylmethane) confers protection against ionizing radiation by a unique mechanism.

Fan S, Meng Q, Xu J, Jiao Y, Zhao L, Zhang X, Sarkar FH, Brown ML, Dritschilo A, Rosen EM.

Proc Natl Acad Sci U S A. 2013 Nov 12;110(46):18650-5. doi: 10.1073/pnas.1308206110. Epub 2013 Oct 14.

44.

Rectal endoscopy findings following stereotactic body radiation therapy for clinically localized prostate cancer.

Sood S, Ju AW, Wang H, Lei S, Uhm S, Zhang G, Suy S, Carroll J, Lynch J, Dritschilo A, Collins SP.

Radiat Oncol. 2013 Aug 9;8:197. doi: 10.1186/1748-717X-8-197.

45.

A response to Sher et al, "Cost-effectiveness analysis of SBRT versus IMRT for low-risk prostate cancer".

Collins SP, Suy S, Chen LN, Collins BT, Dritschilo A.

Am J Clin Oncol. 2013 Jun;36(3):316-7. doi: 10.1097/COC.0b013e318294101b. No abstract available.

PMID:
23681018
46.

Functional proteomics analysis to study ATM dependent signaling in response to ionizing radiation.

Cheema AK, Varghese RS, Timofeeva O, Zhang L, Kirilyuk A, Zandkarimi F, Kaur P, Ressom HW, Jung M, Dritschilo A.

Radiat Res. 2013 Jun;179(6):674-683. doi: 10.1667/RR3198.1. Epub 2013 May 3.

47.

Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience.

Chen LN, Suy S, Uhm S, Oermann EK, Ju AW, Chen V, Hanscom HN, Laing S, Kim JS, Lei S, Batipps GP, Kowalczyk K, Bandi G, Pahira J, McGeagh KG, Collins BT, Krishnan P, Dawson NA, Taylor KL, Dritschilo A, Lynch JH, Collins SP.

Radiat Oncol. 2013 Mar 13;8:58. doi: 10.1186/1748-717X-8-58.

48.

Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer.

Ju AW, Wang H, Oermann EK, Sherer BA, Uhm S, Chen VJ, Pendharkar AV, Hanscom HN, Kim JS, Lei S, Suy S, Lynch JH, Dritschilo A, Collins SP.

Radiat Oncol. 2013 Jan 31;8:30. doi: 10.1186/1748-717X-8-30.

49.

STAT3 suppresses transcription of proapoptotic genes in cancer cells with the involvement of its N-terminal domain.

Timofeeva OA, Tarasova NI, Zhang X, Chasovskikh S, Cheema AK, Wang H, Brown ML, Dritschilo A.

Proc Natl Acad Sci U S A. 2013 Jan 22;110(4):1267-72. doi: 10.1073/pnas.1211805110. Epub 2013 Jan 3.

50.

Use of reprogrammed cells to identify therapy for respiratory papillomatosis.

Yuan H, Myers S, Wang J, Zhou D, Woo JA, Kallakury B, Ju A, Bazylewicz M, Carter YM, Albanese C, Grant N, Shad A, Dritschilo A, Liu X, Schlegel R.

N Engl J Med. 2012 Sep 27;367(13):1220-7.

Supplemental Content

Loading ...
Support Center